Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUNE-LUNG
2023-509490-23-00Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab, pembrolizumab and nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut Bergonié. Primary endpoints: 12-month progression-free rate and 12-month progression-free rate by strategy. Started Jun 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509490-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509490-23-00.